has been found to reduce myocardial β-adrenergic and endothelin-1 signaling, to affect myocardial contractility, to attenuate myocardial ischemia-reperfusion injury, 12 and to have a direct effect on Ca 2+ handling by interaction with calmodulin (CaM) in noncardiac cells. 13 However, currently no information is available in the literature concerning the processing of CgA to shorter peptide fragments in HF. In addition, it is not established whether CgA fragments like CST may directly influence cardiomyocyte function. Although previous studies have reported that CST modulates cardiomyocyte Ca 2+ handling only via indirect mechanisms, 14 this finding is surprising given the direct effect of CST on Ca 2+ handling in noncardiac cells, 13 the influence by other chromogranin-secretogranin proteins on cardiomyocyte Ca 2+ handling, 15 and the ability of CST to directly interact with CaM. 13 CaM is an upstream activator of CaMKIIδ (Ca 2+ /CaM-dependent protein kinase IIδ), which is an established regulator of cardiomyocyte Ca 2+ handling. 16 Because overactive myocardial CaMKIIδ signaling constitutes a central mechanism of HF, direct regulation of this pathway by CST would link CgA and CST directly to CVD. Accordingly, the aims of this study were to characterize CgA processing in acute HF and to explore whether CST directly modulates cardiomyocyte Ca 2+ handling via CaMKIIδ inhibition.
Methods
Details can be found in the Appendix in the Data Supplement. Animal experiments conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The clinical study was performed according to the Declaration of Helsinki, approved by the Regional Ethics Committees, and all participants provided written informed consent before study commencement.
Postinfarction HF Mouse Model and Immunoblotting
Experimental myocardial infarctions were induced by permanent ligation of the main left coronary artery, and the presence of HF was verified by echocardiography 1 week later. 3, 17 Biopsies from the infarcted and noninfarcted left ventricle (LV), right ventricle, and other organs were collected. Deglycosylation was performed by adding different combinations of enzyme cocktails. Short CST fragments were assessed by using a high percentage gel and subjecting the lower part of the membrane to longer exposure.
Clinical Study
We included 314 patients who were hospitalized because of acute dyspnea at Akershus University Hospital, Lørenskog, Norway, into the ACE 2 study (Akershus Cardiac Examination) ( Figure I in the Data Supplement). Patients were characterized as acute HF and acute exacerbation of chronic obstructive pulmonary disease (COPD) by an adjudication committee of 2 experts working independently. 18 CgA levels were measured by ELISA and CST levels by an in-house radioimmunoassay. 19 We calculated the percentage of CgA not converted to CST (CgA-to-CST conversion) in individual patients by this formula: ([CgA−CST]/CgA)×100. High-sensitivity troponin T, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and norepinephrine levels were measured as previously reported.
15
Effect by CST on Ca 2+ Handling
CST-CaMKIIδ interactions were examined by immunoprecipitation, pull-down experiments, and surface plasmon resonance. CaMKIIδ activity was assessed by in vitro kinase activity assays.
Effects of CST on CaMKIIδ, ryanodine receptor 2, and phospholamban (PLB) phosphorylation were studied in Langendorffperfused hearts. BayK was included in the perfusate to promote L-type Ca 2+ channel opening and, thereby, increase CaMKIIδ activity. Adult ventricular cardiomyocytes were isolated as previously reported. 15 Contractions and Ca 2+ transients were elicited by field stimulation, Ca 2+ sparks were measured in resting cells, and cytosolic [Ca 2+ ] was detected by confocal microscopy and wholecell photometry. Cells were preincubated and perfused with 45 nmol/L or 4.5 μmol/L CST.
Statistics
Clinical data are presented as mean±SD and median (quartile 1-3) for biomarkers because of non-normal distributions and experimental data as mean±SEM. Differences between groups were examined by Student's t test or the Mann-Whitney U test, and the Chi-square test and correlation coefficients were calculated by the Spearman rank test. Data with multiple groups were assessed by the Kruskal-Wallis test. We present patients stratified according to biomarker quartiles in Kaplan-Meier plots, and the association with mortality was examined by the log-rank test. Variables associated with mortality in the acute HF patients were also examined by single variable, and multivariable Cox proportional hazard regression analysis with hazard ratios presented with 95% confidence intervals. Variables associated with mortality in single variable analysis were included in the multivariable model (forward selection of variables). P values <0.05 were considered significant.
Results

CgA Is Hyperglycosylated in the Failing Myocardium
Immunoblotting demonstrated high molecular weight (hmw) CgA bands in myocardial biopsies of HF, but not sham-operated animals ( Figure 1A ). Short CgA fragments were observed in sham-operated animals, but to a much lesser degree in HF. The hmw CgA bands were also observed in the right ventricle in HF, but not other organs examined, neither in HF nor in sham-operated animals ( Figure I in the Data Supplement). The short CST fragment was also found to be highly reduced in LV of HF animals compared with CST levels in the LV of sham-operated animals ( Figure 1B ). Adding enzymes that cleaved N-or O-linked glycosylation modifications yielded a shift in the myocardial hmw CgA bands ( Figure 1C ). Combinations of enzymes that cleave O-linked glycosylation also reduced the appearance of hmw CgA bands and yielded an increase in short CgA fragments. The increase in short CgA fragments was most prominent when all enzymes were added in combination ( Figure 1C , right lane).
Circulating CgA Levels Predict Mortality in Acute HF and Reduced CgA-to-CST Conversion Is Associated With a Poor Outcome
In total, 314 patients were included in the ACE 2 Study, and the final diagnosis was acute HF in 143 patients (46%) and acute exacerbation of COPD in 84 patients (27%), while 87 patients (28%) were hospitalized because of non-HF-, non-COPD-related dyspnea ( Figure II in the Data Supplement). Among the patients classified as hospitalized for acute HF, 51 patients (36%) were considered to have HF with preserved LV ejection function (Table I in the Data Supplement). Admission CgA levels, but not CST levels, were higher in the acute HF patients compared with the patients with non-HF-related n=6) . B, By immunoblotting, the short CST fragment was found to be highly reduced in HF animals compared with that in sham-operated animals (n=2). C, Adding enzymes that cleaved N-or O-linked glycosylation modifications yielded a shift in the myocardial hmw CgA bands. Some combination of enzymes also reduced the appearance of hmw CgA bands and yielded an increase in short CgA fragments (n=6). The increase in short fragments was most prominent when all enzymes where added.
dyspnea (Table I in the Data Supplement). The proportion of CgA molecules not converted to CST molecules was also higher in acute HF patients than in the patients with non-HF dyspnea: median 57% versus median 41%, respectively, P=0.001 (Table I in the Data Supplement). Baseline CgA levels in the acute HF patients were inversely correlated with estimated creatinine clearance and diastolic blood pressure on admission, positively correlated with high-sensitivity troponin T and NT-proBNP levels and not significantly correlated with norepinephrine levels (Table II in the Data Supplement). CST levels were inversely correlated with age, but not correlated to other clinical or laboratory variables (Table II in the Data  Supplement) .
During median follow-up of 817 days, 66 patients (46%) with acute HF died, 35 patients (42%) with acute COPD died, and 13 patients (15%) with non-HF and non-COPD-related dyspnea died ( Figure II in the Data Supplement). To include relatively homogenous patient categories with similar mortality rates during follow-up, we selected the patients hospitalized with HF or COPD for further studies. Patients with the highest CgA levels on admission for acute HF had a significantly higher risk of mortality during follow-up compared with the other HF patients (Figure 2A ; P=0.001 by the logrank test). Within 200 days of follow-up, 50% of HF patients with 4th quartile CgA levels had died compared with <10% of HF patients with CgA levels in the 1st quartile. CgA was also found to be a strong prognostic marker in Cox regression analysis, including in multivariable analysis that included NT-proBNP, high-sensitivity troponin T, and norepinephrine levels: hazard ratio (ln CgA per 1 SD increase) 1.51 (95% confidence interval, 1.16-1.95), P=0.002 (Table) . In contrast, baseline CST levels did not predict mortality in patients hospitalized with acute HF (Table and Figure 2B ). Pertinent to this point, patients with low CgA-to-CST conversion had a worse outcome compared with the other HF patients ( Figure 2C ). CgA levels, CST levels, and CgA-to-CST conversion were not associated with mortality in the patients hospitalized 
CST Interacts Directly With CAMKIIδ and Reduces CAMKIIδ Activity
Because we found low CgA-to-CST conversion to be associated with mortality in acute HF, but not in acute exacerbation of COPD, we aimed to explore whether CST may directly affect cardiomyocyte function. The short CgA fragment CST shows sequence similarity to the autoregulatory domain of CaMKIIδ containing the CaM-binding site, which suggests that CST might bind directly to the substrate binding site in the catalytic domain of CaMKIIδ ( Figure 3A) . As predicted by bioinformatics, we identified a CST-CaMKIIδ interaction by immunoprecipitation ( Figure 3B ) and pull-down experiments ( Figure 3C ) using recombinant His-CaMKIIδ (T287D) and biotin-CST. The direct interaction between CST and CaMKIIδ was also demonstrated by surface plasmon resonance analyses with a
, and a k d =(8±3)×10 −4 s −1 ( Figure 3D ). Based on the interaction between CST and CaMKIIδ, we investigated whether CST directly affects CaMKIIδ activity. CaMKIIδ can be autophosphorylated at Thr286 in the regulatory domain of CaMKIIδ, which leads to prolonged kinase activity. 16 We observed that CST reduced the autophosphorylation in BayK-perfused mouse hearts ( Figure 3E ), whereas CST did not reduce the basal level of autophosphorylation ( Figure IVA in the Data Supplement). CST was also observed to strongly inhibit CaMKIIδ activity in a dose-dependent manner in an in vitro kinase assay ( Figure 3F ).
CST Reduces CaMKIIδ-Dependent Phosphorylation of the Ryanodine Receptor 2 and PLB
CaMKIIδ is known to phosphorylate proteins involved in cardiomyocyte Ca 2+ homeostasis, and we examined whether CST could influence ryanodine receptor 2 phosphorylation Figure 2 . Associations between chromogranin A (CgA) levels, catestatin (CST) levels, and CgA-to-CST conversion in patients with acute heart failure (HF). Stratifying patients according to admission (A) CgA quartiles, but not (B) CST quartiles, provided excellent risk stratification in the patients with acute HF. C, Patients with low CgA-to-CST conversion had worse outcome compared with the other HF patients (n=143).
and SERCA via phosphorylation of PLB in isolated perfused mouse hearts. CST reduced both the basal level and the BayK-induced increase in Ser2814-ryanodine receptor 2 phosphorylation ( Figure 4A ; Figure IVB in the Data Supplement), which is regulated by CaMKIIδ. 16 This strong inhibitory effect was not observed at the Ser2808-ryanodine receptor 2 phosphorylation site ( Figure 4B ; Figure IVC in the Data Supplement), which is regulated by protein kinase A. 20 We also found that CST reduced the basal level and the BayK-induced increase in phosphorylation of PLB at Thr17-PLB ( Figure 4C ; Figure IVD 
CST Modulates Cardiomyocyte Ca 2+ Homeostasis
We next examined the effects of CST on Ca 2+ handling in isolated cardiomyocytes. As expected of a CaMKIIδ inhibitor, 21 we observed that CST (4.5 μM) prominently reduced the dimension of Ca 2+ sparks, including the full duration at half-maximum, full width at half-maximum intensity, and the time to peak of the Ca 2+ spark ( Figure 5A ). Ca 2+ spark frequency and Ca 2+ wave frequency were also markedly reduced ( Figure 5A) . A similar reduction in Ca 2+ spark dimensions and the frequency of Ca 2+ sparks and waves was observed when the experiment was repeated with a 100-fold lower CST concentration (45 nmol/L; Figure 5B ), which is in the range of circulating CgA levels in the HF patients. Ca 2+ transients and contractions were larger across a range of stimulation frequencies (1, 0.5, 2, and 5 Hz) ( Figure 6A and 6B). Kinetics of both contraction and relaxation were more rapid in CSTtreated cells than in controls (Figure 6A ), an effect likely explained by faster declining Ca 2+ transients ( Figure 6B ). Frequency-dependent acceleration of relaxation and Ca 2+ transient decline was significantly attenuated in the CST treatment group (Figure 6A and 6B) . Consistent with reduced sarcoplasmic reticulum Ca 2+ leak (sparks; Figure 5 ), we observed that CST treatment increased sarcoplasmic reticulum Ca 2+ content ( Figure 6C) cell or Ca 2+ reuptake into the sarcoplasmic reticulum ( Figure  V in the Data Supplement).
Discussion
The main results of this study are (1) that CgA is hyperglycosylated in the failing myocardium, (2) that the ratio between circulating CgA-to-CST levels, but not CST levels alone, provides prognostic information in patients with acute HF, and (3) that CST has cardioprotective effects via direct CaMKIIδ inhibition. Accordingly, as CaMKII activity is increased in HF, 16 myocardial CgA hyperglycosylation with reduced CgAto-CST processing should be detrimental because of impaired local CaMKII control. Indeed, we found that acute HF patients with low CgA-to-CST conversion had a worse outcome compared with HF patients with higher CgA to CST conversion.
CgA has also previously been recognized as a biomarker that provides prognostic information in patients with CVD. Earlier studies have examined CgA in patients with ACS, [4] [5] [6] HF, [7] [8] [9] and severe sepsis, 10 and in agreement with our present data, these studies found CgA to provide additional prognostic information to established risk indices, including biomarkers and LV function. [4] [5] [6] [8] [9] [10] The complementary information provided by CgA is also reflected by only modest correlations between CgA and BNP (B-type natriuretic peptide) or NT-proBNP levels 4, 6, 7, 9, 10 and no correlation between CgA and catecholamine levels in patients with CVD. 5, 6 We now advance the present knowledge regarding CgA in CVD by demonstrating CgA hyperglycosylation in the failing myocardium and that this may have direct functional consequences via reduced CST-mediated CaMKII inhibition. Based on the knowledge from other proteins, myocardial glycosylation is found to be increased in the failing myocardium and represents a mechanism for posttranslational protein modification. Pertinent to this point, processing of glycosylated proteins can be impaired by sugar groups blocking the binding of proteases to cleavage sites. A prominent example of this is pro-BNP, which is extensively glycosylated in the middle and N-terminal end of the molecule, 18 and where processing to BNP and NT-proBNP is impaired by the glycosylation. As CgA processing takes place at several dibasic cleavage sites along the full-length molecule, 2 extensive CgA glycosylation could influence CgA processing, and our results support this model because short CgA and CST fragments are increased after exposing myocardial biopsies to deglycosylation enzymes. Hence, a substantial proportion of CgA molecules, at least in the failing myocardium, could be glycosylated and, thus, inaccessible for further processing. Additional mechanism for CST removal may be degradation pathways of CgA to fragments other than CST or factors that independently affect the breakdown or stability of CST, which both will have to be assessed in additional studies.
Although no group previously has reported cardiac-specific glycosylation of CgA, we think our results are supported by the literature. A previous report has found circulating CST levels to be reduced in patients with subclinical and established HF compared with subjects free from HF, 22 which supports reduced CgA-to-CST processing as CgA levels are known to be increased in HF patients 8 (as also demonstrated in our clinical cohort). Another group has also reported impaired CgAto-CST processing in myocardial biopsies from aging mice. 23 However, these authors did not report immunoblot bands >100 kDa, and thus, whether the reduction in CST was paralleled by increments in hmw CgA bands is unknown. Still, this study 23 and another more recent study 24 both observed CgA immunoblot bands above the expected full-length molecular weight of 74 kDa in myocardial tissue samples. In contrast, no such bands were evident in adrenal gland tissue samples. These groups also suggested that the myocardial hmw CgA bands could be because of glycosylation, but they did not follow-up on this hypothesis. Finally, using high-performance liquid chromatography to characterize plasma CgA fragments in stable HF patients, Pieroni et al 1 also found peaks with molecular weights above the peak considered representative for full-length-CgA, which could represent the release of glycosylated CgA molecules into the circulation. We found reduced CgA-to-CST conversion to be associated with a poor outcome in acute HF, but not in patients with acute exacerbation of COPD, which supports a role for CST in cardiomyocyte pathophysiology. Based on our data of CST as a CaMKII inhibitor and previous data that found CST to reduce myocardial ischemia-reperfusion injury, 12 increase cardiomyocyte cell survival, 25 and attenuate myocardial β-adrenergic and endothelin-1 signaling, 26 CST seems to be a counter-regulatory paracrine ligand of relevance in CVD. Given the paramount importance of hyperactive CaMKIIδ signaling in CVD, 16 the primary role of CST may be as part of a paracrine/autocrine protective feedback loop that could antagonize overactive myocardial CaMKIIδ signaling. However, our data also indicate that this system may be malfunctioning in a proportion of HF individuals because of myocardial CgA hyperglycosylation. Accordingly, although we previously have reported increased CgA mRNA levels 4 and increased prohormone convertases 1/3 and prohormone convertases 2 activity in the failing myocardium, 17 which are the principal proteases for CgA cleavage, 27 CgA glycosylation could block the binding of these proteases to the full-length molecule and, thus, reduce CST production. Moreover, although a recent report found isoprenalin-and endothelin-infusion to increase myocardial CgA processing in healthy hearts, 24 whether the same increased processing would occur in failing hearts with extensive CgA glycosylation is unknown.
CaMKIIδ is a nodal kinase in the regulation of cardiomyocyte Ca 2+ handling. 16 CaMKIIδ is known to be hyperactive in several cardiac pathologies, including HF, ischemia, remodeling, cardiomyocyte cell death, and arrhythmias. Hence, CaMKIIδ inhibition is recognized as an interesting target for attenuation of disease progression. 16, 28 CST exhibits the CaM-binding motif 1-5-10 and shows homology to the sequence surrounding the core pseudosubstrate site (RKLK) in CaMKIIδ, 29 indicating that CST could also bind to CaMKIIδ. The ability of CST to interact directly with CaMKIIδ is consistent with prior work demonstrating that CST and other granin-derived fragments can bind to CaM in noncardiac cells 13 and to CaM and CaMKIIδ in cardiomyocytes. 15 Our data on Ca 2+ handling in the presence of CST are also consistent with those on CST acting as CaMKIIδ inhibitor because CaMKIIδ inhibition has been found to reduce Ca 2+ spark frequency and magnitude, augment sarcoplasmic reticulum Ca 2+ content, and increase the magnitude of Ca 2+ transients. 21, 30 As expected with CaMKIIδ inhibition, faster transient decay during CST treatment was also associated with more rapid contraction kinetics. 31 CST also blunted frequency-dependent acceleration of relaxation and Ca 2+ transients, a phenomenon reported to result from activation of SERCA at high frequencies, after CaMKIIδ-dependent phosphorylation of PLB at Thr17. 32 The observed effects of CST on cardiomyocyte Ca 2+ handling are in agreement with the effects of other CaMKIIδ inhibitors like KN-93 and AIP 32 and our recent report on the granin protein secretoneurin. 15 Hence, a possible integrated model could be that (1) the most severely ill HF patients increase CgA production as a compensatory mechanism, (2) myocardial hyperglycosylation reduces the effect of this paracrine system by blocking CgA-to-CST conversion, and (3) reduced CST production is detrimental because of lack of local CaMKIIδ control. Based on this model, targeting myocardial CgA hyperglycosylation to increase local CST production could prove valuable as a future strategy to improve outcome in HF. Still, we acknowledge that additional work is needed to decipher the mechanism, whereby the glycosylation occurs and whether interventions to reduce CgA glycosylation would lead to increased myocardial CST levels in subjects with HF. Pertinent to this point, we also found CST to reduce Ser16-PLB phosphorylation, which is not recognized as a CaMKII phosphorylation site. Accordingly, CST could have effects also outside of CaMKII inhibition, including effects via the nitric oxide-cGMP pathway, analogously to data previously demonstrated, 26, 33 or CST could compete with PLB for phosphorylation. Thus, there is a need for experimental studies to establish additional processes that CST could regulate in the failing myocardium, besides CaMKII inhibition, which was the focus of the current work.
In conclusion, we found CgA-to-CST ratio, but not CST alone, to be a valuable prognostic biomarker in acute HF. Moreover, we demonstrate increased myocardial CgA glycosylation and impaired CgA processing in HF, which should be considered detrimental because CST reduces diastolic Ca 2+ leak via direct CaMKIIδ inhibition. Thus, although CgA production seems to increase and probably represent a counterregulatory mechanism in HF, this system may malfunction because of augmented myocardial CgA glycosylation. 2+ transients and reduced the half relaxation time at all frequencies. ***P≤0.001, examined by ANOVA and Kruskal-Wallis test. C, Sarcoplasmic reticulum Ca 2+ content was increased by CST (contractions: Ctr, n hearts =3, n cells =5-12; CST, n hearts =2, n cells =5-8; Ca 2+ transients: Ctr, n hearts =3, n cells =13; CST, n hearts =4, n cells =7; SR content, 10 mmol/L caffeine: Ctr, n hearts =5, n cells =17; CST, n hearts =4, n cells =15). *P≤0.05, examined by Student's t test. Chromogranin A Processing and Calcium Regulation
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